Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis

Award Number: R21CA288674
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/21/2025
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis - Abstract Patients with KRAS-mutated lung cancer have the poorest prognosis and poor response rates to standard cancer treatments. Concurrent LKB1 or TP53 mutations in KRAS-mutated non-small cell lung cancer (NSCLC) define different subgroups of KRAS-mutant NSCLC. There is an urgent need to identify key therapeutical targets in NSCLC. Type I interferons (IFNs), of which the most well-studied are IFNα/β, are known for their anti-viral activities but also play an important role in cancer. IFNε, a unique type I IFN, shares only 30% amino acid homology with IFNα/β and is constitutively expressed in epithelium of mucosal tissues including lung. We have shown that IFNe exhibits distinct functions from IFNa, modulates production of reactive oxygen species and cytokines/chemokines in primary macrophages, and maintains tissue structure and immune homeostasis in mice. Our recent data show that IFNε, overexpressed in cervical cancer tissues, is required for HeLa cell tumorigenic activities and xenograft tumor growth, indicating a novel role of IFNε in tumorigenesis. Moreover, IFNε expression is detected in normal lung tissues and upregulated in KRAS-driven lung tumors. Higher expression of IFNε is associated with poorer survival in lung cancer patients. Given the importance of conventional type I IFNs (e.g., IFNα/β) in tumorigenesis and anti-cancer treatment, understanding the role of IFNε in lung cancer is crucial for identifying new anti-tumor targets. In this proposal, we will determine intrinsic and systemic functions of IFNε in KRAS-driven lung cancer using well-established genetically engineered mouse models of KRAS-driven NSCLC. Our central hypothesis is that aberrant expression of intracellular and extracellular IFNe contributes to lung tumorigenesis by modulating cellular and immune functions. In Aim 1, we will determine the role of tumor-intrinsic IFNε on KRAS-driven lung tumorigenesis. In Aim 2, we will determine the role of systemic IFNε in KRAS-driven lung tumorigenesis. In Aim 3, we will determine whether systemic IFNε deficiency increases the sensitivity of established KRAS-driven lung tumors to immune check blockades. We expect the results of this study will reveal novel cellular and immunological roles of IFNe in KRAS-mutant NSCLC. Identification of IFNe-mediated cellular and immune targets important for tumorigenesis will offer new avenues for development of therapeutic strategies for lung cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $165,145 )
2026	2026	RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	65 BERGEN ST	NEWARK	NJ	07107	ESSEX	USA	Cancer Treatment Research	000	2	2/10/2026	NON-COMPETING CONTINUATION	$165,145
														Subtotal = $165,145

Issue Date FY: 2025 ( Subtotal = $220,193 )
2025	2025	RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	65 BERGEN ST	NEWARK	NJ	07107	ESSEX	USA	Cancer Treatment Research	000	1	2/21/2025	NEW	$220,193
														Subtotal = $220,193

Grand Total All Awards = $385,338

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis

Award Number: R21CA288674

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/21/2025

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer